Veno-occlusive disease after an anti-CD33 therapy (gemtuzumab ozogamicin)

Br J Haematol. 2002 Mar;116(4):924. doi: 10.1046/j.0007-1048.2002.03346.x.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Aged
  • Aminoglycosides*
  • Anti-Bacterial Agents / adverse effects*
  • Anti-Bacterial Agents / therapeutic use*
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Female
  • Gemtuzumab
  • Hepatic Veno-Occlusive Disease / etiology*
  • Humans
  • Leukemia, Myeloid / therapy*
  • Male
  • Middle Aged

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Gemtuzumab